Avalo Therapeutics (AVTX) Non-Current Assets (2014 - 2026)

Avalo Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $11.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 4.51% year-over-year to $11.1 million; the trailing twelve-month figure through Mar 2026 stood at $44.9 million (down 6.77% YoY), and the FY2025 full-year result was $11.2 million, down 5.66% from the prior year.
• Non-Current Assets for Q1 2026 stood at $11.1 million, down from $11.2 million in the prior quarter.
• The five-year high for Non-Current Assets was $18.2 million in Q1 2022, with the low at $11.1 million in Q1 2026.
• Historically, Non-Current Assets has averaged $14.0 million across 5 years, with a median of $12.5 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Assets grew 5.75% — and 2024, when it decreased 26.3%.
• Avalo Therapeutics' Non-Current Assets stood at $17.0 million in 2022, then decreased by 25.68% to $12.6 million in 2023, then fell by 6.0% to $11.8 million in 2024, then slipped by 5.66% to $11.2 million in 2025, then declined by 1.0% to $11.1 million in 2026.
• The last three Non-Current Assets figures came in at $11.1 million (Q1 2026), $11.2 million (Q4 2025), and $11.3 million (Q3 2025), per Business Quant data.